ArticleRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2019
Toward personalized dose-prescription in locally advanced non-small cell lung cancer: Validation of published normal tissue complication probability models.
Article in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 31 citations in OpenAlex.
- Perspectives on the model-based approach to proton therapy trials: A retrospective study of a lung cancer randomized trial.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2020Trial
- Transformer-based cardiac substructure segmentation from contrast and non-contrast computed tomography for radiotherapy planning.Physics and imaging in radiation oncology · 2026Article
- External validation and updating of NTCP models for radiation pneumonitis: QUANTEC, Appelt, and a local simplified model.Frontiers in oncology · 2026Article
- Tumor-conditioned inter-patient registration using planning computed tomography for voxel-based analysis to predict radiation pneumonitis in lung cancer patients.Physics and imaging in radiation oncology · 2026Article
- Prospective validation of a pretreatment 18F-FDG PET/CT and mean lung dose model for early radiation pneumonitis.Physics and imaging in radiation oncology · 2025Article
- [Prognosis-guided optimization of intensity-modulated radiation therapy plans for lung cancer].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- AnJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- ROE (Radiotherapy Outcomes Estimator): An open-source tool for optimizing radiotherapy prescriptions.Computer methods and programs in biomedicine · 2023Article
- Association of cardiac calcium burden with overall survival after radiotherapy for non-small cell lung cancer.Physics and imaging in radiation oncology · 2023Article
- Validation of an established deep learning auto-segmentation tool for cardiac substructures in 4D radiotherapy planning scans.Physics and imaging in radiation oncology · 2022Article
- Radiation-induced lung injury - what do we know in the era of modern radiotherapy?Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2022Review
- Radiomic and Dosiomic Features for the Prediction of Radiation Pneumonitis Across Esophageal Cancer and Lung Cancer.Frontiers in oncology · 2022Article
- Biological dosiomic features for the prediction of radiation pneumonitis in esophageal cancer patients.Radiation oncology (London, England) · 2021Article
- Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer.Nature reviews. Clinical oncology · 2021Review
- Early Prediction of Acute Esophagitis for Adaptive Radiation Therapy.International journal of radiation oncology, biology, physics · 2021Article
- Generalizable cone beam CT esophagus segmentation using physics-based data augmentation.Physics in medicine and biology · 2021Article
- Treatment planning and outcomes effects of reducing the preferred mean esophagus dose for conventionally fractionated non-small cell lung cancer radiotherapy.Journal of applied clinical medical physics · 2021Article
- Predicting spatial esophageal changes in a multimodal longitudinal imaging study via a convolutional recurrent neural network.Physics in medicine and biology · 2020Article
- Radiation-induced lung toxicity - cellular and molecular mechanisms of pathogenesis, management, and literature review.Radiation oncology (London, England) · 2020Review
- Harnessing data science to advance radiation oncology.Molecular oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo identify published normal tissue complication probability (NTCP) models suitable for patient-specific dose-prescription in locally advanced non-small cell lung cancer (LA-NSCLC) through in-house validation. MATERIAL AND
methodsFrom eight previously published candidate NTCP models (≥grade 2 acute esophagitis and radiation pneumonitis; AE2, RP2), patient-specific dose-responses were calculated using model variables and fractionation-corrected doses for 241 LA-NSCLC patients treated with chemo-IMRT to 50-80 Gy@1.8-2.0 Gy between 2004 and 2014 (AE2/RP2 rate: 50%/12%). A model was judged final if it significantly predicted AE2 or RP2 (p ≤ 0.05), was discriminative and well calibrated (AUC > 0.60; Hosmer-Lemeshow test p
resultsModels for AE2 had superior discrimination to RP2 models (AUC = 0.63-0.65 vs. 0.51-0.65). The final AE2 model included mean esophageal dose and concurrent chemotherapy (AUC = 0.65; p < 0.0001). The final RP2 model was a slightly adjusted version of the RP2 model with the best discrimination, and included age, mean lung dose, and pulmonary comorbidity (AUC = 0.73; p < 0.0001).
conclusionOf the eight investigated and published NTCP models, one model successfully described AE2 and one slightly adjusted model successfully described RP2 in the independent cohort. Estimates from these two NTCP models will, therefore, be considered internally when prescribing patient-specific doses in LA-NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.